Familial Transthyretin Amyloidosis Latest Advances

Find the Latest Research About Familial Transthyretin Amyloidosis

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 3386 publications

10 Things Cardiologists Need to Know About Cardiac Amyloidosis

10 Things Cardiologists Need to Know About Cardiac Amyloidosis

Journal: Praxis
Published: September 08, 2026

Autonomic Dysfunction in ATTR Amyloidosis

Autonomic Dysfunction in ATTR Amyloidosis

Journal: Brain and nerve = Shinkei kenkyu no shinpo
Published: August 18, 2026

Epidemiology and burden on the National Health Service of cardiomyopathy associated with transthyretin amyloidosis based on administrative health data.

Epidemiology and burden on the National Health Service of cardiomyopathy associated with transthyretin amyloidosis based on administrative health data.

Journal: Recenti progressi in medicina
Published: July 16, 2026

In memoriam: Shukuro Araki, MD, PhD (1927-2025) pioneer of Japanese neurology and a global leader in familial amyloid polyneuropathy.

In memoriam: Shukuro Araki, MD, PhD (1927-2025) pioneer of Japanese neurology and a global leader in familial amyloid polyneuropathy.

Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
Published: June 29, 2026

Temporal Trends in Incidence and Prevalence of Transthyretin Amyloid Cardiomyopathy in the United States.

Temporal Trends in Incidence and Prevalence of Transthyretin Amyloid Cardiomyopathy in the United States.

Journal: Journal of the American Heart Association
Published: June 23, 2026

Clinical Pharmacology of Eplontersen, the First Approved GalNAc-Conjugated Antisense Oligonucleotide.

Clinical Pharmacology of Eplontersen, the First Approved GalNAc-Conjugated Antisense Oligonucleotide.

Journal: Journal of clinical pharmacology
Published: June 22, 2026

Diagnostic Trends and Geographic Health Care Disparities Among Patients With Transthyretin Amyloid Cardiomyopathy.

Diagnostic Trends and Geographic Health Care Disparities Among Patients With Transthyretin Amyloid Cardiomyopathy.

Journal: Journal of the American Heart Association
Published: June 09, 2026

Impact of Baseline Polyneuropathy Severity on Eplontersen Efficacy in the NEURO-TTRansform Clinical Trial.

Impact of Baseline Polyneuropathy Severity on Eplontersen Efficacy in the NEURO-TTRansform Clinical Trial.

Journal: Journal of the peripheral nervous system : JPNS
Published: June 05, 2026

Differential Effects of Tafamidis on Cardiac Remodelling in Transthyretin Amyloid Cardiomyopathy: Evidence From Contemporary Imaging Data.

Differential Effects of Tafamidis on Cardiac Remodelling in Transthyretin Amyloid Cardiomyopathy: Evidence From Contemporary Imaging Data.

Journal: European journal of clinical investigation
Published: May 30, 2026

Multimodal Artificial Intelligence for Cardiac Amyloidosis Diagnosis: Integrating Echocardiography With Clinical and Laboratory Data for Improved Detection.

Multimodal Artificial Intelligence for Cardiac Amyloidosis Diagnosis: Integrating Echocardiography With Clinical and Laboratory Data for Improved Detection.

Journal: Circulation. Cardiovascular imaging
Published: May 27, 2026

Relevant Adverse Events and Drug Discontinuation of Sacubitril/Valsartan in Patients with Transthyretin Amyloid Cardiomyopathy - Insights from the REVIEW-HF Registry.

Relevant Adverse Events and Drug Discontinuation of Sacubitril/Valsartan in Patients with Transthyretin Amyloid Cardiomyopathy - Insights from the REVIEW-HF Registry.

Journal: International heart journal
Published: May 17, 2026

Pathogenic Characterization of a Novel G47R Transthyretin Mutation in Early-Onset Amyloid Cardiomyopathy.

Pathogenic Characterization of a Novel G47R Transthyretin Mutation in Early-Onset Amyloid Cardiomyopathy.

Journal: Journal of the American Heart Association
Published: May 14, 2026
Showing 1-12 of 3,386

Last Updated: 09/26/2026